The U.S. Food and Drug Administration (FDA) has approved Almirall’s expanded use of Klisyri for actinic keratosis (AK) treatment. This topical field treatment now covers a surface area of up to 100 cm2.

Klisyri, a microtubule inhibitor ointment, comes in two package sizes: 250 mg for treating up to 25 cm2 and 350 mg for up to 100 cm2. The larger treatment area allows clinicians to address more extensive areas of AK on the face or balding scalp.

Clinical studies have shown that Klisyri is safe and well-tolerated in this larger treatment area. The percentage reduction in AK lesion count was comparable to that observed in previous trials using a smaller treatment area.

The expanded use of Klisyri provides increased flexibility for clinicians in treating patients with AK. It allows for more comprehensive treatment and may improve outcomes.

Source link:

author avatar
Ferry Darma
Ferry Darma is Director of Media Relations at The Clinical Trial Vanguard. Ferry, a computer data scientist, focuses on the latest clinical trial industry news and trends.